See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Natural Disasters
Social Media
Eid
Tariffs
Donald Trump
US Politics
Artificial Intelligence
Stock Markets
Education
Taxes
Senate
Baseball
Published • loading... • Updated

Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

Summary by Eagle-Tribune
- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -

2 Articles

All
Left
Center
1
Right
Eagle-TribuneEagle-Tribune
Center

Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -

Read Full Article
stocktitan.netstocktitan.net

First Look: Vaxcyte Reveals Phase 2 Data for Next-Gen Infant Pneumococcal Vaccine

Key efficacy and safety data comparing VAX-24 to Prevnar 20 in preventing pneumococcal disease in infants. Full analysis and trial implications inside.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news in on Sunday, March 30, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal